Solid Tumor Oncology
Research activity is centered on advanced solid tumors, with a focus on treatment settings where disease control remains difficult and therapeutic options are limited. The sponsor’s clinical work includes a basket trial framework spanning multiple tumor types.
- Advanced solid tumors
- Basket trial oncology
- Combination cancer therapy
The clinical portfolio reflects interest in oncology programs that evaluate new agents alongside established standard-of-care approaches.
Hepatobiliary Cancer
One key area of interest is cholangiocarcinoma, a rare and aggressive bile duct cancer with significant unmet need. The sponsor’s trial activity in this space is directed toward patients with advanced disease.
- Cholangiocarcinoma
- Biliary tract malignancies
- Advanced hepatobiliary cancer
This area highlights attention to difficult-to-treat gastrointestinal and hepatobiliary malignancies within the broader oncology program.
Head and Neck Oncology
The sponsor also studies head and neck cancer, focusing on tumors that often require multimodal treatment and remain challenging in advanced stages. This interest extends to disease settings where new therapeutic combinations are being explored.
- Head and neck cancer
- Squamous cell carcinoma
- Advanced head and neck malignancies
Clinical activity in this field aligns with efforts to address refractory disease and improve options for patients with limited responses to existing therapies.
Combination Therapeutics
The trial landscape includes evaluation of LSTA1 with standard-of-care therapies, indicating a therapeutic focus on combination strategies in oncology. This area centers on integration with established cancer regimens rather than single-agent development alone.
- LSTA1 combination therapy
- Standard-of-care oncology regimens
- Therapeutic combination studies
Current research activity is concentrated in the United States, with collaborating sites supporting clinical investigation across multiple oncology settings.
